Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) shares saw unusually-strong trading volume on Wednesday . Approximately 610,343 shares changed hands during trading, an increase of 456% from the previous session's volume of 109,755 shares.The stock last traded at $8.86 and had previously closed at $8.74.
Shionogi & Co., Ltd. Unsponsored ADR Stock Performance
The stock has a 50-day moving average of $8.56 and a 200 day moving average of $8.01. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.63 and a quick ratio of 6.13.
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last issued its earnings results on Monday, July 28th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.02. The business had revenue of $672.90 million for the quarter, compared to analysts' expectations of $719.55 million. Sell-side analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current fiscal year.
About Shionogi & Co., Ltd. Unsponsored ADR
(
Get Free Report)
Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.
Further Reading
Before you consider Shionogi & Co., Ltd. Unsponsored ADR, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shionogi & Co., Ltd. Unsponsored ADR wasn't on the list.
While Shionogi & Co., Ltd. Unsponsored ADR currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access